

PRIOR AUTHORIZATION REQUEST

Doptelet

Patient Information:			
Name:			
Member ID:			
Address:			
City, State, Zip:			
Date of Birth:			
Dragaribar Information			
Prescriber Information: Name:			
NPI:			
Phone Number:			
Fax Number			
Address:			
City, State, Zip:			
Requested Medication			
Rx Name:			
Rx Strength			
Rx Quantity:			
Rx Frequency:			
Rx Route of			
Administration:			
Diagnosis and ICD Code:			
prescribed a medication for your quantities can be provided. Plea Upon receipt of the completed SECTION A: Please no requests. Pharmacy primedications that are not	efit requires that we review certain requests for coverage with the prescriber. You have repatient that requires Prior Authorization before benefit coverage or coverage of additional ase complete the following questions then fax this form to the toll-free number listed below. It does not be plan's rules of the supporting clinical documentation is required for ALL PA or authorization reviews can be subject to trial with additional of listed within the criteria. The policies are subject to change based its, MDH transmittals and updates to treatment guidelines.		
1 What is the diagnos	eis or indication?		
	in patients with chronic liver disease (If checked, go to 2)		
[] Chronic immune th	Chronic immune thrombocytopenia (If checked, go to 5)		
[] Other (If checked, r	no further questions)		
2 What is the patient' [] Greater than or equ	's age? ual to 18 years of age (If checked, go to 3)		

If you have any questions, call: 1-888-258-8250

PRIOR AUTHORIZATION REQUEST

[] Less than 18 years of age (If checked, no further questions) 3				
Sol.000 per microliter)? [If no, no further questions.] Is the patient scheduled to undergo a procedure within 10 to 13 days after starting Doptelet therapy? [No further questions.] Sol. the request for initial therapy or continuation of therapy? [Initial therapy (If checked, go to 6) Continuation of therapy (If checked, go to 12) Continuation of therapy (If checked, go to 12) What is the patient's age? Continuation of therapy (If checked, go to 12) Continuation of therapy (If checked, go to 7) Less than 18 years of age (If checked, no further questions) Is the requested medication prescribed by or in consultation with a hematologist? Yes No [If no, no further questions.] Yes No [If no, no further questions.] Yes No [If no, no further questions.] Yes No If no, no further question Yes No If yes, skip to question 10.] Yes No If yes, skip to question 10.] Yes No If no, no further questions.] Yes No Solooo/microliter) Yes No Solooomicroliter) Yes No Yes Yes		[] Less than 18 years of age (If checked, no further questions)		
Doptelet therapy? [No further questions.] Is the request for initial therapy or continuation of therapy? [Initial therapy (If checked, go to 6) [Continuation of therapy (If checked, go to 12) What is the patient's age? [Greater than or equal to 18 years of age (If checked, go to 7) [Less than 18 years of age (If checked, no further questions) Is the requested medication prescribed by or in consultation with a hematologist? Yes No [If no, no further questions.] Has the patient tried one other therapy? [Note: Examples of therapies are systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, Promacta (eltrombopag tablets and oral suspension), Nplate (romiplostim injection for subcutaneous use), Tavalisse (fostamatinib tablets), and rituximab.] [If yes, skip to question 10.] Has the patient undergone a splenectomy? [If no, no further questions.] Does the patient have a platelet count of less than 30 x 10^9/L (less than 30,000/microliter)? [If yes, no further questions.] Does the patient have a platelet count of less than 50 x 10^9/L (less than 50,000/microliter) and is at an increased risk of bleeding, according to the prescriber? [No further questions.]	3	50,000 per microliter)?	Yes	No
[] Initial therapy (If checked, go to 6) [] Continuation of therapy (If checked, go to 12) 6 What is the patient's age? [] Greater than or equal to 18 years of age (If checked, go to 7) [] Less than 18 years of age (If checked, no further questions) 7 Is the requested medication prescribed by or in consultation with a hematologist? Yes No [If no, no further questions.] 8 Has the patient tried one other therapy? [Note: Examples of therapies are systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, Promacta (eltrombopag tablets and oral suspension), Nplate (romiplostim injection for subcutaneous use), Tavalisse (fostamatinib tablets), and rituximab.] [If yes, skip to question 10.] 9 Has the patient undergone a splenectomy? [If no, no further questions.] 10 Does the patient have a platelet count of less than 30 x 10^9/L (less than 30,000/microliter)? [If yes, no further questions.] 11 Does the patient have a platelet count of less than 50 x 10^9/L (less than 50,000/microliter) and is at an increased risk of bleeding, according to the prescriber? [No further questions.] 12 Has the patient demonstrated a beneficial clinical response (for example, increased platelet counts), according to the prescriber? [If no, no further questions.]	4	Doptelet therapy?	Yes	No
What is the patient's age? [] Greater than or equal to 18 years of age (If checked, go to 7) [] Less than 18 years of age (If checked, no further questions) 7	5			
[] Greater than or equal to 18 years of age (If checked, go to 7) [] Less than 18 years of age (If checked, no further questions) 7		[] Continuation of therapy (If checked, go to 12)		
Is the requested medication prescribed by or in consultation with a hematologist? Yes No [If no, no further questions.] Has the patient tried one other therapy? [Note: Examples of therapies are systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, Promacta (eltrombopag tablets and oral suspension), Nplate (romiplostim injection for subcutaneous use), Tavalisse (fostamatinib tablets), and rituximab.] [If yes, skip to question 10.] Has the patient undergone a splenectomy? [If no, no further questions.] Does the patient have a platelet count of less than 30 x 10^9/L (less than 30,000/microliter)? [If yes, no further questions.] Does the patient have a platelet count of less than 50 x 10^9/L (less than 50,000/microliter) and is at an increased risk of bleeding, according to the prescriber? [No further questions.] Has the patient demonstrated a beneficial clinical response (for example, increased platelet counts), according to the prescriber? [If no, no further questions.]	6			
[If no, no further questions.] 8		[] Less than 18 years of age (If checked, no further questions)		
[Note: Examples of therapies are systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, Promacta (eltrombopag tablets and oral suspension), Nplate (romiplostim injection for subcutaneous use), Tavalisse (fostamatinib tablets), and rituximab.] [If yes, skip to question 10.] 9 Has the patient undergone a splenectomy? [If no, no further questions.] 10 Does the patient have a platelet count of less than 30 x 10^9/L (less than 30,000/microliter)? [If yes, no further questions.] 11 Does the patient have a platelet count of less than 50 x 10^9/L (less than 50,000/microliter) and is at an increased risk of bleeding, according to the prescriber? [No further questions.] 12 Has the patient demonstrated a beneficial clinical response (for example, increased platelet counts), according to the prescriber? [If no, no further questions.]	7		Yes	No
[If no, no further questions.] 10 Does the patient have a platelet count of less than 30 x 10^9/L (less than 30,000/microliter)? [If yes, no further questions.] 11 Does the patient have a platelet count of less than 50 x 10^9/L (less than 50,000/microliter) and is at an increased risk of bleeding, according to the prescriber? [No further questions.] 12 Has the patient demonstrated a beneficial clinical response (for example, increased platelet counts), according to the prescriber? [If no, no further questions.]	8	[Note: Examples of therapies are systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, Promacta (eltrombopag tablets and oral suspension), Nplate (romiplostim injection for subcutaneous use), Tavalisse (fostamatinib tablets), and rituximab.]	Yes	No
30,000/microliter)? [If yes, no further questions.] 11 Does the patient have a platelet count of less than 50 x 10^9/L (less than 50,000/microliter) and is at an increased risk of bleeding, according to the prescriber? [No further questions.] 12 Has the patient demonstrated a beneficial clinical response (for example, increased platelet counts), according to the prescriber? [If no, no further questions.]	9	· · · · · · · · · · · · · · · · · · ·	Yes	No
50,000/microliter) and is at an increased risk of bleeding, according to the prescriber? [No further questions.] Has the patient demonstrated a beneficial clinical response (for example, Yes No increased platelet counts), according to the prescriber? [If no, no further questions.]	10	30,000/microliter)?	Yes	No
increased platelet counts), according to the prescriber? [If no, no further questions.]	11	50,000/microliter) and is at an increased risk of bleeding, according to the prescriber?	Yes	No
13 Does the patient remain at risk for bleeding complications? Yes No	12	increased platelet counts), according to the prescriber?	Yes	No
	13	Does the patient remain at risk for bleeding complications?	Yes	No

If you have any questions, call: 1-888-258-8250



PRIOR AUTHORIZATION REQUEST

	_
Please document the diagnoses, symptoms, and/or any other	er information important to this review:
SECTION B: Physician Signature	
DI IVOICIANI CIONATUDE	DATE
PHYSICIAN SIGNATURE	DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.